Search results for "Pharmacokinetics"

showing 8 items of 458 documents

Renal Allograft Compartment Syndrome: Is It Possible to Prevent?

2016

Renal allograft compartment syndrome (RACS) is a complication characterized by increased pressure over 15 to 20 mm Hg of the iliac fossa site of transplanted kidney that can lead to a reduction of the blood supply to the graft, resulting in organ ischemia. This study aims to evaluate, through a review of the literature, the incidence, detection, treatment, and possible prevention of RACS. The incidence of this complication, which appears generally in the immediate post-transplantation period, is currently approximately 1% to 2% and is underestimated because of poor nosography for the presence of symptoms common to other post-transplantation complications. Doppler ultrasound is indispensable…

medicine.medical_specialtymedicine.medical_treatmentIschemiaIliac fossa030230 surgeryCompartment SyndromesAbdominal wall03 medical and health sciences0302 clinical medicinePostoperative ComplicationsmedicineHumansCompartment (pharmacokinetics)Reduction (orthopedic surgery)Transplantationbusiness.industryIncidence (epidemiology)Abdominal Wound Closure Techniquesmedicine.diseaseDecompression SurgicalKidney TransplantationSurgery; TransplantationSurgerySettore MED/18 - Chirurgia Generalemedicine.anatomical_structureEarly Diagnosis030220 oncology & carcinogenesisRenal allograftSurgeryComplicationbusinessTransplantation proceedings
researchProduct

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

2022

Background Circulating dysfunctional factor IX (FIX) might modulate distribution of infused FIX in hemophilia B (HB) patients. Recurrent substitutions at FIX activation sites (R191-R226, >300 patients) are associated with variable FIX activity and antigen (FIXag) levels. Objectives To investigate the (1) expression of a complete panel of missense mutations at FIX activation sites and (2) contribution of F9 genotypes on the FIX pharmacokinetics (PK). Methods We checked FIX activity and antigen and activity assays in plasma and after recombinant expression of FIX variants and performed an analysis of infused FIX PK parameters in patients (n = 30), mostly enrolled in the F9 Genotype and PK HB …

medicine.medical_specialtypharmacogenetics.Mutation MissenseSocio-culturaleAlpha (ethology)aemophilia Brecombinant proteinsHemophilia Blaw.inventionFactor IXAntigenlawInternal medicineGenotypemedicineMissense mutationHumansHaemophilia BpharmacokineticBeta (finance)Factor IXpharmacogeneticsChemistryHematologymedicine.diseaseEndocrinologyPhenotypefactor IX activation; hemophilia B; pharmacogenetics; pharmacokinetics; recombinant proteinsRecombinant DNAFemalefactor IX activationBlood Coagulation Testspharmacokineticsrecombinant proteinmedicine.drugJournal of thrombosis and haemostasis : JTH
researchProduct

Enantioselective determination of plasma protein binding of common amphetamine-type stimulants.

2021

Amphetamine-type stimulants (ATS) like amphetamine ('speed'), methamphetamine ('crystal meth') and 3,4-methylenedioxy-N-methylamphetamine (MDMA, 'ecstasy') represent some of the most frequently abused drugs worldwide. Another less frequently abused ATS is 4-fluoroamphetamine (4-FA). The enantiomers of these four compounds exhibit different pharmacokinetic and pharmacodynamic properties. According to the free drug theory, the pharmacological properties of a substance are dependent on its plasma protein binding (PPB). However, data on PPB of stimulant enantiomers in humans are rare or non-existent. Human plasma samples were spiked with racemic mixtures of the stimulants and subjected to ultra…

medicine.medical_treatmentClinical BiochemistryPharmaceutical ScienceTandem mass spectrometryAnalytical ChemistryPharmacokineticsTandem Mass SpectrometryDrug DiscoverymedicineHumansAmphetamineSpectroscopyChromatographyChemistryIllicit DrugsForensic toxicologyMDMAStereoisomerismMethamphetamineStimulantAmphetamineCentral Nervous System StimulantsEnantiomermedicine.drugChromatography LiquidProtein BindingJournal of pharmaceutical and biomedical analysis
researchProduct

Pharmacokinetics of new oral anticoagulants: implications for use in routine care

2018

Introduction: Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant–TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages. In clinical practice, pharmacokinetic aspects of NOACs have to be carefully taken into account to …

medicine.medical_treatmentnew oral anticoagulantsAdministration OralKnee replacement030204 cardiovascular system & hematologyToxicologyAdherence Bleeding Interactions New oral anticoagulants Over- and under-dosage Persistence Pharmacokinetics Real World Evidence0302 clinical medicineAtrial Fibrillationover- and underdosage030212 general & internal medicinepharmacokineticStrokeRoutine careRandomized Controlled Trials as Topicnew oral anticoagulantAtrial fibrillationpersistenceVenous ThromboembolismGeneral MedicinePulmonary embolismStrokepharmacokineticsHumanmusculoskeletal diseasesmedicine.medical_specialtyinteractionHemorrhageMedication Adherence03 medical and health sciencesPharmacokineticsmedicineHumansReal World EvidenceIn patientOver- and under-dosagecardiovascular diseasesreal-world evidenceIntensive care medicineAgedPharmacologybusiness.industryAnticoagulantAnticoagulantsinteractionsbleedingmedicine.diseaseAdherencePulmonary EmbolismbusinessVenous thromboembolismExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Editorial: Flavonoids: From Biosynthesis and Metabolism to Health Benefits

2021

descripción no proporcionada por scopus

pinostrobin pharmacokineticsCatechin galloylationPinostrobin pharmacokineticsanthocyanin contentcatechin galloylationFlavonoidVitexinHydroxysafflor Yellow APlant SciencePharmacologySB1-1110chemistry.chemical_compoundmedicineFormononetinVitexinisoflavonesAnthocyanin contentchemistry.chemical_classificationFormononetinXanthohumolPlant cultureMetabolismIsoflavonesIsoflavonesxanthohumolchemistryMechanism of actionPolyphenolhydroxysafflor Yellow AXanthohumolmedicine.symptomFrontiers in Plant Science
researchProduct

In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Inje…

2021

This study evaluated in vitro and in vivo drug release of bedaquiline from in situ forming gels (ISGs) containing 200 mg eq./g bedaquiline fumarate salt prepared with four different grades of poly(d,l-lactide) (PDLLA) or poly(d,l-lactide-co-glycolide) (PLGA) with a lactide/glycolide ratio of 50/50 or 75/25 and acid (A) or ester (E) end-capping in N-methyl-2-pyrrolidone at a polymer/solvent ratio of 20/80% (w/w). Mean in vitro drug release in 0.05 M phosphate buffer pH 7.4 with 1% (w/v) sodium lauryl sulphate was 37.3, 47.1, 53.3, and 62.3% within 28 days for ISGs containing PLGA5050A, PDLLA, PLGA7525A, and PLGA7525E, respectively. The data suggested that drug release was primarily controlle…

porosityBedaquilinein vitro releasePharmaceutical SciencedissolutionPolyethylene glycolArticleDiffusionchemistry.chemical_compoundSubcutaneous injectionPharmacy and materia medicaPharmacokineticsIn vivoPharmacokineticsin situ forming gelsSolubilitybedaquilinesustained releaseinjectableLactidepolymer erosionPharmacology. TherapydiffusionIn vitro releasePolymer erosionRS1-441PLGAInjectablechemistryIn situ forming gelsBedaquilinePorositypharmacokineticsDissolutionNuclear chemistrySustained releasePharmaceutics
researchProduct

Aportación de la monitorización farmacocinética de vancomicina a la calidad farmacoterapéutica y seguridad del paciente neonato prematuro

2014

Vancomicina es un antibiótico utilizado con gran frecuencia en pacientes neonatos prematuros ingresados en las Unidades de Cuidados Intensivos Neonatales. La elevada variabilidad en los parámetros farmacocinéticos en este grupo de población representa la mayor barrera en el desarrollo y en la optimización de regímenes de dosificación. Esta situación favorece el desarrollo de diversas recomendaciones basadas en modelos farmacocinéticos poblacionales y nomogramas de dosificación, que consideran, para el cálculo de la dosis, variables como la edad postconcepcional, postnatal, creatinina sérica o el peso de los pacientes. Sin embargo, la experiencia clínica ha puesto de relieve que las concentr…

vancomicinavancomycinUNESCO::CIENCIAS MÉDICASneonatos:CIENCIAS MÉDICAS [UNESCO]farmacocinéticaneonatespharmacokinetics
researchProduct

Voltammetric determination of platinum in perfusate and blood: Preliminary data on pharmacokinetic study of arterial infusion with oxaliplatin

2012

Abstract Because Platinum Group Elements have found widespread use in catalytic converters in cars and as chemotherapeutic agent, interest in the development of reliable analytical methods is carried out in order to monitor these analita in humans to protect the citizen's health. Considering that information on the levels of many trace elements in biological matrices is scarce and for many non-essential elements, baseline levels in the population, and especially in those particularly exposed to the risk are lacking, in this paper we optimize an analytical method for biological matrices, using a voltammetric technique to measure the concentration of Pt in blood and perfusate. The amount of P…

voltammetryeducation.field_of_studyChromatographyPopulationAnalytical chemistryPtchemistry.chemical_elementBiological materialsAnalytical ChemistryOxaliplatinchemistryPharmacokineticsbloodperfusatemedicineSettore CHIM/01 - Chimica AnaliticaIn patientPlatinumeducationVoltammetrySpectroscopyTarget organmedicine.drugMicrochemical Journal
researchProduct